ProFound Therapeutics, a company pioneering the expanded human proteome to develop medicines, has announced a four-year ...

Novartis and ProFound Therapeutics have entered into a four-year partnership aimed at discovering and developing new ...

Novartis is penning a four-year pact with ProFound Therapeutics to create new therapeutics for heart disease, with $750 ...

Using the ProFoundry platform and Novartis' expertise, the partners will identify novel proteins and drug targets for cardiovascular disease.

ProFound Therapeutics enters multi-year strategic collaboration with Novartis to discover and develop novel therapeutics for cardiovascular disease: Cambridge, Massachusetts Frida ...

Cambridge, USA-based ProFound Therapeutics today announced a four-year collaboration with Swiss pharma giant Novartis to ...

Novartis AG has agreed to buy U.S. biotech firm Regulus Therapeutics Inc. in a deal that could be valued at up to $1.7 billion. The Swiss company will pay $7 a share in cash up-front through a ...

But Novartis stock climbed 1.4% to close at 112.26 as Travere stock fell 7.7%, closing at 16.56. Novartis Stock: A Long History Behind Atrasentan.

FRANKFURT (Reuters) -Novartis said on Monday that its targeted radiotherapy Pluvicto was shown to slow progression of a certain type of prostate cancer, raising the prospect of treatment in an ...

Swiss pharmaceutical firm Novartis on Tuesday reported better-than-expected first-quarter sales and raised its full-year guidance. Net sales were up 15% on a constant currency basis to $13.2 ...

The Novartis Gene Therapies manufacturing facility on Tricenter Blvd. in Durham, N.C., just outside Research Triangle Park. Brian Gordon Swiss pharmaceutical giant Novartis has exited one of its ...

ProFound Therapeutics Announces Multi-Year Strategic Collaboration with Novartis to Discover and Develop Novel Therapeutics for Cardiovascular Disease Provided by GlobeNewswire Jun 26, 2025, 10:30 ...